Related Experiment Video
Updated: Apr 11, 2026

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
Published on: January 7, 2019
Differences in Response to Antiretroviral Therapy by Sex and Hepatitis C Infection Status
Julia L Marcus1, Wendy A Leyden1, Chun R Chao2
11 Kaiser Permanente Northern California , Oakland, California.
Insights
Hepatitis C virus (HCV) co-infection slows CD4 recovery and increases mortality in adults with HIV starting antiretroviral therapy (ART). Aggressive HCV treatment is recommended for all co-infected individuals, irrespective of sex.
Area of Science:
- Infectious Diseases
- Immunology
- Public Health
Background:
- Hepatitis C virus (HCV) co-infection and biological sex are potential factors influencing antiretroviral therapy (ART) response in HIV-infected individuals.
- Limited research exists on the combined impact of HCV status and sex on HIV-associated outcomes.
- Understanding these interactions is crucial for optimizing HIV management.
Purpose of the Study:
- To investigate the effects of HCV co-infection and biological sex on CD4 cell count changes, viral load suppression, and survival in HIV-infected adults initiating ART.
- To determine if HIV/HCV co-infection influences ART effectiveness differently based on sex.
- To provide evidence for tailored treatment strategies in co-infected populations.
Main Methods:
- A cohort study of 12,865 HIV-infected adults initiating ART between 1996-2011 was conducted.
- Piecewise linear regression analyzed CD4 count changes over 5 years, stratified by sex and HCV status.
- Cox regression assessed hazards for viral suppression (<500 copies/mL), AIDS, and death, considering sex and HCV co-infection.
Main Results:
- HIV/HCV co-infected individuals (both men and women) exhibited slower CD4 count increases in the first year of ART compared to HIV-mono-infected individuals.
- After 5 years, women maintained higher CD4 counts than men, irrespective of HCV status.
- HIV/HCV co-infection was associated with a 40% increased mortality risk but did not significantly impact AIDS incidence or viral suppression rates compared to HIV mono-infection.
Conclusions:
- HIV/HCV co-infected men and women experience impaired CD4 recovery and elevated mortality risk following ART initiation.
- Biological sex influences CD4 count trajectories, with women generally showing better recovery.
- Aggressive treatment of HCV in co-infected adults, regardless of sex, is strongly recommended to improve long-term outcomes.
Abstract:
Hepatitis C virus (HCV) co-infection and biological sex may each affect response to antiretroviral therapy (ART), yet no studies have examined HIV-associated outcomes by both HCV status and sex. We conducted a cohort study of HIV-infected adults initiating ART in Kaiser Permanente California during 1996-2011. We used piecewise linear regression to assess CD4 changes by sex and HCV status over 5 years. We used Cox regression to estimate hazard ratios (HR) by sex and HCV status for HIV RNA <500 copies/mL over 1 year, and for AIDS and death over the follow-up period. Among 12,865 subjects, there were 154 HIV/HCV-co-infected women, 1000 HIV/HCV-co-infected men, 1088 HIV-mono-infected women, and 10,623 HIV-mono-infected men. CD4 increases were slower in the first year for HIV/HCV-co-infected women (75 cells/μL) and men (70 cells/μL) compared with HIV-mono-infected women (145 cells/μL) and men (120 cells/μL; p<0.001). After 5 years, women had higher CD4 than men in both HIV-mono-infected (598 vs. 562 cells/μL, p=0.003) and HIV/HCV-co-infected individuals (567 vs. 509 cells/μL, p=0.003). Regardless of sex, HIV/HCV co-infection was associated with 40% higher mortality [95% confidence interval (CI): 1.2-1.6] compared with HIV mono-infection, but was not associated with AIDS (HR 1.1, 95% CI: 0.9-1.3) or achieving HIV RNA <500 copies/mL (HR 1.0, 95% CI: 0.9-1.1). HIV/HCV-co-infected men and women have slower CD4 recovery after starting ART and have increased mortality compared with HIV-mono-infected men and women. HCV should be aggressively treated in HIV/HCV-co-infected adults, regardless of sex.
Related Concept Videos
Retrovirus Life Cycles
Hepatitis
Sexually Transmitted Infections
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Retroviruses
Inhibitors of Viral Protein Synthesis

